Kineta Cuts Deal With MPI

Xconomy Seattle — 

Seattle-based Kineta, the company developing drugs against autoimmune diseases, said today it has formed an alliance with MPI Research. Terms of the deal weren’t disclosed, but Kineta will get support for animal studies that will enable it to start clinical trials in 2010, the company said. Kineta also received the second year of funding under a grant from the National Institutes of Health to advance its antiviral research program. We profiled Kineta and its unusual strategy back in July when it acquired drug candidates for multiple sclerosis and other autoimmune disorders.